Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $50.0 million.

  • Nurix Therapeutics' Non-Current Assets rose 42.24% to $81.9 million in Q3 2025 from the same period last year, while for Aug 2025 it was $81.9 million, marking a year-over-year increase of 42.24%. This contributed to the annual value of $50.0 million for FY2024, which is 16.87% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Non-Current Assets of $50.0 million as of FY2024, which was down 16.87% from $60.1 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Non-Current Assets peaked at $165.7 million during FY2021, and registered a low of $50.0 million during FY2024.
  • Over the past 3 years, Nurix Therapeutics' median Non-Current Assets value was $60.1 million (recorded in 2023), while the average stood at $69.5 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Non-Current Assets skyrocketed by 1,985.83% in 2020, and later tumbled by 40.65% in 2022.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Non-Current Assets stood at $97.9 million in 2020, then surged by 69.19% to $165.7 million in 2021, then plummeted by 40.65% to $98.3 million in 2022, then crashed by 38.87% to $60.1 million in 2023, then decreased by 16.87% to $50.0 million in 2024.